Биомаркеры диабетической ретинопатии

Ф. М. Урманова, Ф. А. Бахритдинова, А. А. Ахраров, Guzal Kangilbaeva

Передовая Офтальмология · 2023-yil

Annotatsiya

Relevance. Despite modern advances in medicine, type 2 diabetes mellitus (DM 2) still remains an important medical and social problem due to the frequency and severity of complications. The purpose of our study. The aim of the study was to evaluate the relationship between the levels of vascular growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) in blood serum and the area of the foveal avascular zone (FAZ) on OCT-A in patients with type 2 diabetes mellitus (DM2), with various stages DR. Materials and methods. A clinical study was conducted among 252 people (n=504), of which 168 patients with type 2 diabetes and 84 practically healthy individuals, the average age of which was 57.6 ± 7.8 years, of which 52.6% were men, 47.4% women. Results. As a result of the studies, an increase in the level of VEGF in the blood serum before the onset of DR clinically was revealed 137.2 ± 84.4 pg/ml (group II of comparison). It was found that the level of VEGF correlated with the levels of BDNF in the serum of patients and with the stage of retinopathy (p<0.05). Based on the studies performed, it was suggested that a mild deficiency with plasma BDNF less than 0.62 ng/ml indicates DR in general, and a BDNF level < 0.22 ng/ml indicates the development of PDR and/or diabetic macular ischemia (DME). Thus, a low level of BDNF and a high level of VEGF in serum can be potential risk factors for DR in T2 DM and serve as its diagnostic indicators.

Maqola ma’lumotlari
MualliflarФ. М. Урманова, Ф. А. Бахритдинова, А. А. Ахраров, Guzal Kangilbaeva
JurnalПередовая Офтальмология
NashriyotБухоро давлат тиббиёт институти
ISSN2181-4236, 2181-4244
Nashr sanasi2023-02-22
Jild1
Son1
Betlar170-173
TilRus
Ilmiy sohaTibbiyot
DOI10.57231/j.ao.2023.1.1.039
Indeksga qo‘shilgan2026-09-02

DOI: 10.57231/j.ao.2023.1.1.039 · Maqolaning asl sahifasi · PDF

Ilmiy soha

Tibbiyot

Iqtibos keltirish

APAФ. М. Урманова, Ф. А. Бахритдинова, А. А. Ахраров, & Guzal Kangilbaeva (2023). БИОМАРКЕРЫ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ. Передовая Офтальмология, 1(1), 170-173. https://doi.org/10.57231/j.ao.2023.1.1.039
GOST (OAK)Ф. М. Урманова va b. БИОМАРКЕРЫ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ // Передовая Офтальмология. – 2023. – T. 1, № 1. – С. 170-173. – DOI: 10.57231/j.ao.2023.1.1.039.
MLAФ. М. Урманова, Ф. А. Бахритдинова, А. А. Ахраров, and Guzal Kangilbaeva. “БИОМАРКЕРЫ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ.” Передовая Офтальмология, 1(1), 170-173, 2023. https://doi.org/10.57231/j.ao.2023.1.1.039
ChicagoФ. М. Урманова, Ф. А. Бахритдинова, А. А. Ахраров, and Guzal Kangilbaeva. “БИОМАРКЕРЫ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ.” Передовая Офтальмология, 1(1), 170-173 (2023). https://doi.org/10.57231/j.ao.2023.1.1.039
HarvardФ. М. Урманова, Ф. А. Бахритдинова, А. А. Ахраров, and Guzal Kangilbaeva (2023) ‘БИОМАРКЕРЫ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ’, Передовая Офтальмология, 1(1), 170-173. https://doi.org/10.57231/j.ao.2023.1.1.039
BibTeX
@article{article2023,
  title = {БИОМАРКЕРЫ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ},
  author = {Ф. М. Урманова and Ф. А. Бахритдинова and А. А. Ахраров and Guzal Kangilbaeva},
  journal = {Передовая Офтальмология},
  year = {2023},
  volume = {1},
  number = {1},
  pages = {170-173},
  doi = {10.57231/j.ao.2023.1.1.039},
  url = {https://doi.org/10.57231/j.ao.2023.1.1.039}
}

Boshqa maqola uchun iqtibos tayyorlash

Передовая Офтальмология jurnalidan boshqa maqolalar

Передовая Офтальмология — barcha maqolalar · 2023-yil arxivi

Tibbiyot sohasidagi boshqa maqolalar

Tibbiyot sohasidagi OAK jurnallari